• EN - English
  • MT - Malti
Parliamentary question - E-002521/2017Parliamentary question
E-002521/2017

Asthma treatment in Europe

Question for written answer E-002521-17
to the Commission
Rule 130
David Casa (PPE)

Asthma remains a very common disease in the European Union, with an estimated 8% of adults and 9% of children suffering from some form of it. The European Asthma Research and Innovation Partnership (EARIP) has suggested that national and regional treatment programmes are more successful than generalised guidelines for all countries.

How, if at all, does the Commission participate in best-practice sharing between national and regional treatment providers?

Will the Commission seek to expand the EARIP in the coming years?

How does the Commission feel an increase in the prevalence of asthma among children and young people can be prevented?